ストックスクリーナーアプリを入手
75.21
5.37%
3.83
プレマーケット:
75.00
-0.21
-0.28%
前日終値:
$71.38
開ける：
$73
24時間の取引高:
3.97M
Relative Volume:
1.69
時価総額：
$10.21B
収益：
$105.82M
当期純損益:
$-829.61M
株価収益率:
-10.99
EPS:
-6.8429
ネットキャッシュフロー:
$-548.92M
1週間 パフォーマンス:
+9.88%
1か月 パフォーマンス:
-0.84%
6か月 パフォーマンス:
+21.27%
1年 パフォーマンス:
+122.65%
1日の値動き範囲:
$72.15
$77.00
1週間の範囲:
$66.63
$77.00
52週間の値動き範囲:
$31.99
$80.20
Cytokinetics Inc Stock (CYTK) Company Profile
名前
Cytokinetics Inc
セクター
電話
(650) 624-3000
住所
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
75.21 | 9.69B | 105.82M | -829.61M | -548.92M | -6.8429 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-10 | 開始されました | Wells Fargo | Overweight |
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2025-12-18 | アップグレード | Goldman | Neutral → Buy |
| 2025-07-30 | 再開されました | Raymond James | Mkt Perform |
| 2025-04-24 | 開始されました | Barclays | Overweight |
| 2025-02-07 | 開始されました | Citigroup | Buy |
| 2025-01-22 | 開始されました | Stifel | Buy |
| 2024-11-08 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-08-13 | ダウングレード | Goldman | Buy → Neutral |
| 2024-01-24 | ダウングレード | UBS | Buy → Neutral |
| 2024-01-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | 開始されました | Goldman | Buy |
| 2023-11-07 | 開始されました | B. Riley Securities | Buy |
| 2023-08-15 | 開始されました | SVB Securities | Outperform |
| 2023-02-17 | 開始されました | BofA Securities | Neutral |
| 2022-12-23 | 繰り返されました | Needham | Buy |
| 2022-12-20 | 開始されました | Truist | Buy |
| 2022-10-11 | 開始されました | UBS | Buy |
| 2022-01-28 | 開始されました | Goldman | Buy |
| 2021-12-22 | 開始されました | Oppenheimer | Outperform |
| 2021-12-10 | 開始されました | JP Morgan | Overweight |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-03-12 | 開始されました | Wolfe Research | Outperform |
| 2021-02-18 | 開始されました | Barclays | Overweight |
| 2021-01-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-29 | 開始されました | Goldman | Neutral |
| 2020-07-10 | 開始されました | Raymond James | Strong Buy |
| 2020-05-05 | 開始されました | Mizuho | Buy |
| 2020-04-09 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-10 | 再開されました | Morgan Stanley | Equal-Weight |
| 2017-11-22 | 繰り返されました | Morgan Stanley | Overweight |
| 2017-11-22 | ダウングレード | Needham | Strong Buy → Buy |
| 2017-11-21 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-07-31 | 開始されました | Morgan Stanley | Overweight |
| 2017-03-08 | 開始されました | Rodman & Renshaw | Buy |
| 2017-02-06 | アップグレード | Needham | Buy → Strong Buy |
| 2016-12-16 | 開始されました | Cantor Fitzgerald | Overweight |
| 2016-07-28 | 繰り返されました | Needham | Buy |
| 2015-11-10 | 繰り返されました | FBR Capital | Outperform |
| 2015-11-09 | 繰り返されました | ROTH Capital | Buy |
| 2015-07-24 | 繰り返されました | MLV & Co | Buy |
| 2014-12-31 | 繰り返されました | ROTH Capital | Buy |
| 2014-11-04 | アップグレード | MLV & Co | Hold → Buy |
| 2014-04-28 | 繰り返されました | Needham | Buy |
すべてを表示
Cytokinetics Inc (CYTK) 最新ニュース
Cytokinetics (CYTK) CEO Robert Blum sells 7,500 shares in open market trade - Stock Titan
Cytokinetics, Inc. (CYTK) Stock Analysis: Tapping into a Potential 49% Upside in the Biotech Sector - DirectorsTalk Interviews
Cytokinetics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Cytokinetics (CYTK) Launches MYQORZO in Germany for Obstructive HCM Treatment - Yahoo Finance
Cytokinetics, Incorporated Stock 12‑Month Price Target Raised to $106.58, Implies 52% Upside - TradingView
Monashee Investment Management LLC Sells 25,000 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics, Incorporated $CYTK Shares Acquired by GW&K Investment Management LLC - MarketBeat
Insider Sell Alert: Fady Malik Sells 3,500 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics EVP Malik sells $237,930 in shares By Investing.com - Investing.com Australia
Cytokinetics EVP Malik sells $237,930 in shares - Investing.com India
Cytokinetics (CYTK) EVP exercises options and sells 3,500 shares - Stock Titan
Nonprofits can seek up to $20K from Cytokinetics for health equity - Stock Titan
First MYQORZO Launch In Germany Might Change The Case For Investing In Cytokinetics (CYTK) - Yahoo Finance
807,070 Shares in Cytokinetics, Incorporated $CYTK Acquired by Norges Bank - MarketBeat
Cytokinetics, Inc. (CYTK) Stock Analysis: A Promising Biotech Player with Potential 46.47% Upside - DirectorsTalk Interviews
Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program - Yahoo Finance
Cytokinetics, Incorporated $CYTK Stake Trimmed by TD Asset Management Inc - MarketBeat
Total liabilities & shareholders' equities of Cytokinetics, Incorporated – XETR:KK3A - TradingView
CYTK Q1 2026 Earnings: Narrower-Than-Expected Loss as Pipeline Progress ContinuesEarnings Power Value - newsline.com
Long term debt to total assets ratio of Cytokinetics, Incorporated – XETR:KK3A - TradingView
ETFs Investing in Cytokinetics, Incorporated Stocks - TradingView
Cytokinetics, Incorporated Trade Ideas — XETR:KK3A - TradingView
Cytokinetics prices $700 million stock offering at $71 per share - Investing.com
Truist raises Cytokinetics stock price target on positive trial data - Investing.com
J.P. Morgan Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $97 - Moomoo
Cytokinetics says MYKORZO launch tops expectations as HCM data draws praise - MSN
Cytokinetics prices public offering of 9.8 mln shares at $71/share - marketscreener.com
Cytokinetics Inc (CYTK) News, Articles, Events & Latest Updates - Stocktwits
Why Is Cytokinetics (CYTK) Down 5.5% Since Last Earnings Report? - Yahoo Finance
BNP Paribas Financial Markets Purchases 332,397 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat
Cytokinetics earnings on deck as trial results loom large By Investing.com - Investing.com Australia
Cytokinetics director Parshall sells $370,400 of CYTK stock By Investing.com - Investing.com South Africa
Insider Sell Alert: Kaye Edward M. MD Sells Shares of Cytokineti - GuruFocus
Cytokinetics EVP Andrew Callos sells $1.11m in stock By Investing.com - Investing.com Australia
Insider Sell Alert: B Parshall Sells 5,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics director Edward Kaye sells $223,171 in shares By Investing.com - Investing.com Australia
Cytokinetics EVP Andrew Callos sells $1.11m in stock - Investing.com
Cytokinetics director Edward Kaye sells $223,171 in shares - Investing.com
Cytokinetics director Parshall sells $370,400 of CYTK stock - Investing.com
Cytokinetics (CYTK) director Kaye sells 2,933 shares at $76.09 - Stock Titan
CYTOKINETICS (CYTK) CCO exercises options and sells 15,000 shares at $74.08 - Stock Titan
Director Parshall trims Cytokinetics (CYTK) stake with 5,000-share sale - Stock Titan
[144] CYTOKINETICS INC SEC Filing - Stock Titan
Cytokinetics (CYTK) Launches Myqorzo in Germany for Heart Condition Treatment - GuruFocus
Cytokinetics announces launch of Myqorzo (aficamten) in Germany for symptomatic obstructive hypertrophic cardiomyopathy - marketscreener.com
Cytokinetics launches heart drug Myqorzo in Germany By Investing.com - Investing.com Australia
Cytokinetics launches heart drug Myqorzo in Germany - Investing.com
Cytokinetics Announces European Launch of MYQORZO® (aficamten) for Obstructive Hypertrophic Cardiomyopathy in Germany Following U.S. Approval - Quiver Quantitative
Cytokinetics launches Myqorzo® (aficamten) in European Union, with first commercial availability in Germany - marketscreener.com
Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany - The Manila Times
New heart drug MYQORZO reaches German patients with obstructive HCM - Stock Titan
Cytokinetics Inc (CYTK) 財務データ
収益
当期純利益
現金流量
EPS
Cytokinetics Inc (CYTK) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | EVP Research & Development |
Jun 09 '26 |
Option Exercise |
7.80 |
3,500 |
27,300 |
157,402 |
| Malik Fady Ibraham | EVP Research & Development |
Jun 09 '26 |
Sale |
67.98 |
3,500 |
237,930 |
153,902 |
| Kaye Edward M. MD | Director |
Jun 01 '26 |
Sale |
76.09 |
2,933 |
223,172 |
10,283 |
| Callos Andrew | EVP, Chief Commercial Officer |
Jun 01 '26 |
Option Exercise |
23.26 |
15,000 |
348,900 |
73,555 |
| Callos Andrew | EVP, Chief Commercial Officer |
Jun 01 '26 |
Sale |
74.08 |
15,000 |
1,111,200 |
58,555 |
| PARSHALL B LYNNE | Director |
Jun 01 '26 |
Sale |
74.08 |
5,000 |
370,400 |
15,784 |
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):